Skip to main content
SpringerLink
Log in

The Authors’ Reply

  • Correspondence
  • Published:
Drugs & Aging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Parodi V, de Florentiis D, Martini M, et al. Inactivated influenza vaccines: recent progress and implications for the elderly. Drugs Aging 2011; 28(2): 93–106

    Article  PubMed  CAS  Google Scholar 

  2. Lang PO. Inactivated influenza vaccines: pre-vaccination haemagglutinin-antibody titres influence the vaccine response but not necessarily the vaccine effectiveness. Drugs Aging 2011; 28(6): 505

    Article  PubMed  Google Scholar 

  3. Väänänen P, Mäkelä P, Vaheri A. Effect of low level immunity on response to live rubella virus vaccine. Vaccine 1986; 4: 5–8

    Article  PubMed  Google Scholar 

  4. Powers DC, Murphy BR, Fries LF, et al. Reduced infectivity of cold-adapted influenza A H1N1 viruses in the elderly: correlation with serum and local antibodies. J Am Geriatr Soc 1992; 40: 163–7

    PubMed  CAS  Google Scholar 

  5. Lauterbach H, Ried C, Epstein AL, et al. Reduced immune responses after vaccination with a recombinant herpes simplex virus type 1 vector in the presence of antiviral immunity. J Gen Virol 2005; 86: 2401–10

    Article  PubMed  CAS  Google Scholar 

  6. He XS, Holmes TH, Sasaki S, et al. Baseline levels of influenza-specific CD4 memory T-cells affect T-cell responses to influenza vaccines. PLoS One 2008; 3: e2574

    Article  PubMed  Google Scholar 

  7. Schuller E, Klade CS, Heinz FX, et al. Effect of pre-existing anti-tick-borne encephalitis virus immunity on neutralising antibody response to the Vero cell-derived, inactivated Japanese encephalitis virus vaccine candidate IC51. Vaccine 2008; 26: 6151–6

    Article  PubMed  CAS  Google Scholar 

  8. Pine SO, Kublin JG, Hammer SM, et al. Pre-existing adenovirus immunity modifies a complex mixed Th1 and Th2 cytokine response to an Ad5/HIV-1 vaccine candidate in humans. PLoS One 2011; 6(4): e18526

    Article  PubMed  CAS  Google Scholar 

  9. Nicholson KG, Colegate AE, Podda A, et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001; 357: 1937–43

    Article  PubMed  CAS  Google Scholar 

  10. Heijmans S, De Meulemeester M, Reynders P, et al. Immunogenicity profile of a 3.75-microg hemagglutinin pandemic rH5N1 split virion AS03A-adjuvanted vaccine in elderly persons: a randomized trial. J Infect Dis 2011 Apr; 203(8): 1054–62

    Article  PubMed  CAS  Google Scholar 

  11. Davenport FM, Hennesey AV, Francis T. Epidemiologic and immunologic significance of age distribution of antibody to antigenic variants of influenza virus. J Exp Med 1953; 99: 641–56

    Article  Google Scholar 

  12. de St Groth F, Webster RG. Discussions of original antigenic sin: I. Evidence in man. J Exp Med 1966; 124: 331–45

    Article  Google Scholar 

  13. Ansaldi F, Zancolli M, Durando P, et al. Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates. Vaccine 2010; 28: 4123–9

    Article  PubMed  CAS  Google Scholar 

  14. Ansaldi F, Bacilieri S, Durando P, et al. Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. Vaccine 2008; 26: 1525–9

    Article  PubMed  CAS  Google Scholar 

  15. Hirota Y, Kaji M, Goto S, et al. The hemagglutination inhibition antibody responses to an inactivated influenza vaccine among healthy adults with special reference to the prevaccination antibody and its interaction with age. Vaccine 1996; 14: 1597–602

    Article  PubMed  CAS  Google Scholar 

  16. Masurel N, Laufer J. A one-year study of trivalent influenza vaccines in primed and unprimed volunteers: immunogenicity, clinical reactions and protection. J Hyg (Lond) 1984; 92: 263–76

    Article  CAS  Google Scholar 

  17. Hobson D, Curry RL, Beare AS, et al. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972; 70(4): 767–77

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Filippo Ansaldi has acted as a speaker and on advisory boards for Sanofi Pasteur, GlaxoSmithKline and Novartis, and has received research funding from Sanofi Pasteur, GlaxoSmithKline, Berna Biotech and Novartis. The other authors have no conflicts of interest that are directly relevant to the content of this letter.

Author information

Authors and Affiliations

  1. Department of Health Sciences, University of Genoa, Genoa, Italy

    Valentina Parodi, Daniela de Florentiis & Filippo Ansaldi

Authors
  1. Valentina Parodi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniela de Florentiis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Filippo Ansaldi
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Parodi, V., de Florentiis, D. & Ansaldi, F. The Authors’ Reply. Drugs Aging 28, 505–507 (2011). https://doi.org/10.2165/11592360-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11592360-000000000-00000

Keywords

Search

Navigation